TYRA (Tyra Biosciences) Research & Development: $111.43 Mil (TTM As of Mar. 2026)


TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $31.88
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Research & Development?

Tyra Biosciences TYRA +3.07% 28 Research & Development is $111.43 Mil as of Mar. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tyra Biosciences's Research & Development for the three months ended in Mar. 2026 was $33.47 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $111.43 Mil.

Tyra Biosciences  (NAS:TYRA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tyra Biosciences Research & Development Related Terms

Tyra Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences Research & Development Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 20.64 43.01 62.52 80.08 102.93

Tyra Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.96 24.31 25.47 28.19 33.47
TYRA
28GF Score
Tyra Biosciences Inc TYRA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $111.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $111.43 Mil mean?
Tyra Biosciences (TYRA) has a Research & Development of $111.43 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tyra Biosciences and its competitors.
Is Tyra Biosciences' Research & Development too high?
Tyra Biosciences' current Research & Development is $111.43 Mil. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Research & Development compare to ZLAB and OCUL?
Tyra Biosciences' Research & Development of $111.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current Research & Development is $111.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Research & Development of $111.43 Mil. The current Research & Development is $111.43 Mil. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Research & Development is $111.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.88
Price